About InterMune
InterMune is a company based in Brisbane (United States) founded in 1998 was acquired by Legacy Pharma in February 2025. The company has 359 employees as of December 31, 2014. InterMune operates in a competitive market with competitors including Zai Lab, aTyr Pharma, ReCode Therapeutics, GEn1E and Pulmatrix, among others.
- Headquarter Brisbane, United States
- Employees 359 as on 31 Dec, 2014
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Roche
& 1 more
-
Employee Count
359
as on Dec 31, 2014
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of InterMune
Detailed funding history for InterMune
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in InterMune
InterMune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Roche and Legacy Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Locked | Locked | Locked | |
|
Legacy Pharma is engaged in distributing prescription pharmaceutical products.
|
Locked | Locked | Locked |
Investor details for InterMune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InterMune
Investment portfolio details for InterMune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InterMune
Detailed financials for InterMune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intermune Comparisons
Peer comparison for InterMune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InterMune
InterMune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zai Lab, aTyr Pharma, ReCode Therapeutics, GEn1E and Pulmatrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
Detailed competitors of InterMune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intermune
Complete news archive for InterMune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterMune
InterMune was founded in 1998.
InterMune is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
As of Dec 31, 2014, the latest employee count at InterMune is 359.
InterMune was founded in 1998 and is headquartered in Brisbane, United States. Operations in the biotechnology sector center on research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases. Idiopathic pulmonary fibrosis is addressed through Pirfenidone, approved in the EU as Esbriet and under Phase 3 trials for U.S. registration. Small-molecule therapeutics and biomarkers are pursued for monitoring serious pulmonary conditions.
InterMune's top competitors include Zai Lab, aTyr Pharma and ReCode Therapeutics.
InterMune has 2 investors. Key investors include Roche, and Legacy Pharma.